Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic bone marrow + anti-thymocyte globulin + sirolimus
- Development stage
- Unknown
- Lead developer
- National Institute of Diabetes and Digestive and Kidney Diseases
- Modality
- Cell Therapies, Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This experimental combination therapy regimen, developed by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), is designed to induce donor-specific immunologic hyporesponsiveness in kidney transplant recipients. The protocol involves the administration of Thymoglobulin (a rabbit-derived anti-thymocyte globulin) for T-cell depletion, sirolimus (an mTOR inhibitor) for maintenance immunosuppression, and an infusion of allogeneic donor bone marrow cells. The primary objective of this approach is to promote graft tolerance and reduce the long-term reliance on standard immunosuppressive drugs, which are often associated with chronic nephrotoxicity and other systemic side effects.
- Other names
- Thymoglobulin + sirolimus + donor bone marrow infusionATG + sirolimus + bone marrowAllogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay)
02
Targets
mTOR (Mammalian target of rapamycin kinase)pMHC–TCR (Peptide–MHC–T-cell receptor complex)
Beyond the preview
Go deeper on allogeneic bone marrow + anti-thymocyte globulin + sirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic bone marrow + anti-thymocyte globulin + sirolimus.